RecruitingPhase 3NCT07661056

Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease

A Phase 3, Double-blind, Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of BHV-1300 in the Treatment of Adults With Graves' Disease

Sponsor

Biohaven Therapeutics Ltd.

Enrollment

300 participants

Start Date

Jun 26, 2026

Study Type

INTERVENTIONAL

Conditions

Graves Disease

Summary

The purpose of this study is to evaluate the efficacy and safety of BHV-1300 in adult participants with Graves' disease who are actively hyperthyroid

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called BHV-1300 and a drug called Placebo for people with graves disease. The study is currently recruiting participants at 24 locations. People eligible for this study include aged 18 Years to 70 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBHV-1300

delivered subcutaneously via autoinjector

DRUGPlacebo

delivered subcutaneously via autoinjector

Locations(44)

Site-044

Tucson, Arizona, United States

Site-032

Burbank, California, United States

Site-062

Huntington Beach, California, United States

Site-048

Oakland, California, United States

Site-006

San Diego, California, United States

Site-067

Walnut Creek, California, United States

Site-052

Doral, Florida, United States

Site-066

Fort Myers, Florida, United States

Site-019

Hialeah, Florida, United States

Site-061

Miami, Florida, United States

Site-059

Palm Beach Gardens, Florida, United States

Site-074

Tampa, Florida, United States

Site-029

Atlanta, Georgia, United States

Site-053

Fayetteville, Georgia, United States

Site-031

Champaign, Illinois, United States

Site-080

Springfield, Illinois, United States

Site-025

Lenexa, Kansas, United States

Site-046

Farmington Hills, Michigan, United States

Site-072

Las Vegas, Nevada, United States

Site-038

Asheville, North Carolina, United States

Site-011

Greenville, North Carolina, United States

Site-063

Morehead City, North Carolina, United States

Site-064

Morehead City, North Carolina, United States

Site-039

Raleigh, North Carolina, United States

Site-033

Statesville, North Carolina, United States

Site-045

Wilmington, North Carolina, United States

Site-008

Canton, Ohio, United States

Site-037

Norman, Oklahoma, United States

Site-016

Chattanooga, Tennessee, United States

Site-017

Memphis, Tennessee, United States

Site-081

Amarillo, Texas, United States

Site-055

Dallas, Texas, United States

Site-020

Dallas, Texas, United States

Site-043

Denton, Texas, United States

Site-042

El Paso, Texas, United States

Site-034

Houston, Texas, United States

Site-071

Houston, Texas, United States

Site-054

McKinney, Texas, United States

Site-057

San Antonio, Texas, United States

Site-036

Shavano Park, Texas, United States

Site-009

Weslaco, Texas, United States

Site-013

Layton, Utah, United States

Site-073

Midlothian, Virginia, United States

Site-076

Seattle, Washington, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07661056

Related Trials

Validating Immunological Markers Associated With Mental Fatigue in Graves' Disease

NCT060814391 location

A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old

NCT07722546

Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease

NCT0768289630 locations

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

NCT07018323154 locations

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

NCT06727604134 locations